News
OTLC
0.042
+2.44%
0.001
Weekly Report: what happened at OTLC last week (0629-0703)?
Weekly Report · 8h ago
Oncotelic CEO, Chairman Trieu Vuong reports purchase of 240,000 common shares valued at $10,344
PUBT · 3d ago
Oncotelic Therapeutics Enters New Convertible Note Financing
TipRanks · 6d ago
Oncotelic evaluates IV everolimus candidate Sapu003 in Phase 1b trial for advanced solid tumors
PUBT · 06/29 12:30
Weekly Report: what happened at OTLC last week (0622-0626)?
Weekly Report · 06/29 09:10
Oncotelic Therapeutics Chairman and CEO Trieu Vuong acquires $11,475 of common shares
PUBT · 06/25 00:38
Oncotelic CFO Amit Shah reports purchase of common shares worth $1,000
PUBT · 06/22 20:31
Weekly Report: what happened at OTLC last week (0615-0619)?
Weekly Report · 06/22 09:11
Oncotelic collaborates with TechForce Robotics on AI-enabled GMP manufacturing platform
PUBT · 06/18 12:09
Insider Power Move: Oncotelic’s Top Executive Quietly Boosts His Stake
TipRanks · 06/18 02:03
Nightfood unit TechForce Robotics deploys PUR-E robot at SAPU Bio sterile injectable facility
PUBT · 06/17 12:31
Oncotelic teams with TechForce Robotics on AI-powered GMP manufacturing platform at SAPU Bio joint venture
PUBT · 06/17 12:01
Weekly Report: what happened at OTLC last week (0608-0612)?
Weekly Report · 06/15 09:11
Weekly Report: what happened at OTLC last week (0601-0605)?
Weekly Report · 06/08 09:10
ONCOTELIC THERAPEUTICS INC. (OTCQB: OTLC) EYEING NANOTECH-DRIVEN DELIVERY SYSTEMS, PHARMACOKINETIC OPTIMIZATION TO ADVANCE EXISTING ONCOLOGY THERAPIES
Reuters · 06/04 12:30
Oncotelic expands Phase 1b Sapu003 trial into Europe, appoints Global Clinical Trials as lead CRO
PUBT · 06/03 12:33
SAPU NANO EXPANDS INTERNATIONAL DEVELOPMENT OF SAPU003 AND APPOINTS GLOBAL CLINICAL TRIALS (GCT) AS LEAD CRO FOR PHASE 1B PROGRAM
Reuters · 06/03 12:30
Oncotelic teams with TechForce Robotics to co-develop lab, pharma automation systems
PUBT · 06/01 11:45
Weekly Report: what happened at OTLC last week (0525-0529)?
Weekly Report · 06/01 09:11
Oncotelic CEO presents Deciparticle nanomedicine platform at BIO International Convention 2026
PUBT · 05/28 12:32
More
Webull provides a variety of real-time OTLC stock news. You can receive the latest news about Oncotelic Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.